# Rapport Therapeutics, Inc.: financial statements, quarterly

RAPP · Nasdaq · CIK 2012593 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rapp.md) · [Financials](/companies/rapp/financials.md) · [Filings](/companies/rapp/filings.md) · [Insiders](/companies/rapp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rapp/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-210355.md) | [0.0](/filings/0001193125-26-333862.md) | not reported | not reported | [20.0](/filings/0001193125-26-210355.md) | [0.0](/filings/0001193125-26-333862.md) |
| Research and development | $m | [7.6](/filings/0000950170-24-122801.md) | [11.8 d](/filings/0000950170-25-036828.md) | [12.5](/filings/0000950170-25-066393.md) | [15.7](/filings/0000950170-25-104565.md) | [15.5](/filings/0001193125-25-268096.md) | [17.2 d](/filings/0001193125-26-099360.md) | [19.6](/filings/0001193125-26-210355.md) | [22.7](/filings/0001193125-26-333862.md) | [22.3](/filings/0001193125-25-268096.md) | [30.3 d](/filings/0001193125-26-099360.md) | [32.7](/filings/0001193125-26-210355.md) | [51.4](/filings/0001193125-26-333862.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | [7.5](/filings/0001193125-26-210355.md) | [6.8](/filings/0001193125-26-333862.md) | not reported | not reported | [11.5](/filings/0001193125-26-210355.md) | [9.4](/filings/0001193125-26-333862.md) |
| Operating income | $m | [(9.6)](/filings/0000950170-24-122801.md) | [(14.8) d](/filings/0000950170-25-036828.md) | [(17.1)](/filings/0000950170-25-066393.md) | [(20.8)](/filings/0000950170-25-104565.md) | [(21.6)](/filings/0001193125-25-268096.md) | [(23.5) d](/filings/0001193125-26-099360.md) | [(27.1)](/filings/0001193125-26-210355.md) | [(29.5)](/filings/0001193125-26-333862.md) | [(30.0)](/filings/0001193125-25-268096.md) | [(38.5) d](/filings/0001193125-26-099360.md) | [(24.2)](/filings/0001193125-26-210355.md) | [(60.8)](/filings/0001193125-26-333862.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-122801.md) | [0.0 d](/filings/0000950170-25-036828.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(8.7)](/filings/0000950170-24-122801.md) | [(13.5) d](/filings/0000950170-25-036828.md) | [(22.7)](/filings/0001193125-25-268096.md) | [(18.1)](/filings/0001193125-25-268096.md) | [(17.5)](/filings/0001193125-25-268096.md) | [(20.0) d](/filings/0001193125-26-099360.md) | [(24.1)](/filings/0001193125-26-333862.md) | [(26.7)](/filings/0001193125-26-333862.md) | [(26.9)](/filings/0001193125-25-268096.md) | [(33.8) d](/filings/0001193125-26-099360.md) | [(19.9)](/filings/0001193125-26-333862.md) | [(56.6)](/filings/0001193125-26-333862.md) |
| Diluted EPS | $ per share | [(5.70)](/filings/0000950170-24-122801.md) | not reported | [(11.07)](/filings/0000950170-25-066393.md) | [(1.70)](/filings/0000950170-25-104565.md) | [(0.50)](/filings/0001193125-25-268096.md) | not reported | [(0.68)](/filings/0001193125-26-210355.md) | [(0.75)](/filings/0001193125-26-333862.md) | [(0.71)](/filings/0001193125-25-268096.md) | not reported | [(0.42)](/filings/0001193125-26-210355.md) | [(1.19)](/filings/0001193125-26-333862.md) |
| Basic EPS | $ per share | [(5.70)](/filings/0000950170-24-122801.md) | not reported | [(11.07)](/filings/0000950170-25-066393.md) | [(1.70)](/filings/0000950170-25-104565.md) | [(0.50)](/filings/0001193125-25-268096.md) | not reported | [(0.68)](/filings/0001193125-26-210355.md) | [(0.75)](/filings/0001193125-26-333862.md) | [(0.71)](/filings/0001193125-25-268096.md) | not reported | [(0.42)](/filings/0001193125-26-210355.md) | [(1.19)](/filings/0001193125-26-333862.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [159](/filings/0000950170-24-122801.md) | [70.2](/filings/0000950170-25-036828.md) | [74.3](/filings/0000950170-25-066393.md) | [110](/filings/0000950170-25-104565.md) | [39.3](/filings/0001193125-25-268096.md) | [56.8](/filings/0001193125-26-099360.md) | [57.6](/filings/0001193125-26-210355.md) | [55.1](/filings/0001193125-26-333862.md) | [251](/filings/0001193125-25-268096.md) | [52.6](/filings/0001193125-26-333862.md) | [78.1](/filings/0001193125-26-210355.md) | [63.6](/filings/0001193125-26-333862.md) |
| Current assets | $m | not reported | [151](/filings/0000950170-25-036828.md) | not reported | [341](/filings/0000950170-24-093334.md) | [326](/filings/0000950170-24-122801.md) | [310](/filings/0001193125-26-099360.md) | [291](/filings/0000950170-25-066393.md) | [270](/filings/0000950170-25-104565.md) | [521](/filings/0001193125-25-268096.md) | [499](/filings/0001193125-26-333862.md) | [485](/filings/0001193125-26-210355.md) | [447](/filings/0001193125-26-333862.md) |
| Total assets | $m | not reported | [155](/filings/0000950170-25-036828.md) | not reported | [346](/filings/0000950170-24-093334.md) | [331](/filings/0000950170-24-122801.md) | [315](/filings/0001193125-26-099360.md) | [302](/filings/0000950170-25-066393.md) | [285](/filings/0000950170-25-104565.md) | [535](/filings/0001193125-25-268096.md) | [512](/filings/0001193125-26-333862.md) | [498](/filings/0001193125-26-210355.md) | [459](/filings/0001193125-26-333862.md) |
| Current liabilities | $m | not reported | [8.8](/filings/0000950170-25-036828.md) | not reported | [8.1](/filings/0000950170-24-093334.md) | [7.1](/filings/0000950170-24-122801.md) | [8.8](/filings/0001193125-26-099360.md) | [9.4](/filings/0000950170-25-066393.md) | [11.9](/filings/0000950170-25-104565.md) | [14.3](/filings/0001193125-25-268096.md) | [19.0](/filings/0001193125-26-333862.md) | [17.9](/filings/0001193125-26-210355.md) | [28.4](/filings/0001193125-26-333862.md) |
| Total liabilities | $m | not reported | [14.5](/filings/0000950170-25-036828.md) | not reported | [9.2](/filings/0000950170-24-093334.md) | [8.0](/filings/0000950170-24-122801.md) | [9.5](/filings/0001193125-26-099360.md) | [16.2](/filings/0000950170-25-066393.md) | [22.0](/filings/0000950170-25-104565.md) | [23.7](/filings/0001193125-25-268096.md) | [27.8](/filings/0001193125-26-333862.md) | [26.1](/filings/0001193125-26-210355.md) | [36.1](/filings/0001193125-26-333862.md) |
| Shareholders' equity | $m | [(13.1)](/filings/0000950170-24-122801.md) | [(25.6)](/filings/0001193125-26-099360.md) | [(39.6)](/filings/0001193125-25-268096.md) | [337](/filings/0001193125-25-268096.md) | [323](/filings/0001193125-25-268096.md) | [305](/filings/0001193125-26-333862.md) | [286](/filings/0001193125-26-333862.md) | [264](/filings/0001193125-26-333862.md) | [512](/filings/0001193125-25-268096.md) | [485](/filings/0001193125-26-333862.md) | [472](/filings/0001193125-26-333862.md) | [423](/filings/0001193125-26-333862.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.4) d](/filings/0000950170-24-122801.md) | [(10.4) d](/filings/0000950170-25-036828.md) | [(17.6)](/filings/0000950170-25-066393.md) | [(16.4) d](/filings/0000950170-25-104565.md) | [(16.4) d](/filings/0001193125-25-268096.md) | [(14.4) d](/filings/0001193125-26-099360.md) | [(20.2)](/filings/0001193125-26-210355.md) | [(25.1) d](/filings/0001193125-26-333862.md) | [(17.5) d](/filings/0001193125-25-268096.md) | [(24.7) d](/filings/0001193125-26-099360.md) | [(13.1)](/filings/0001193125-26-210355.md) | [(41.5) d](/filings/0001193125-26-333862.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-122801.md) | [1.4 d](/filings/0000950170-25-036828.md) | [1.1](/filings/0000950170-25-066393.md) | [1.0 d](/filings/0000950170-25-104565.md) | [0.1 d](/filings/0001193125-25-268096.md) | [0.2 d](/filings/0001193125-26-099360.md) | [0.3](/filings/0001193125-26-210355.md) | [0.0 d](/filings/0001193125-26-333862.md) | [0.1 d](/filings/0001193125-25-268096.md) | [0.2 d](/filings/0001193125-26-099360.md) | [0.1](/filings/0001193125-26-210355.md) | [0.1 d](/filings/0001193125-26-333862.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-06-30) | period not labelled (2023-09-30) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.4](/filings/0000950170-24-093334.md) | [1.5](/filings/0000950170-24-122801.md) | [2.0](/filings/0000950170-25-066393.md) | [10.7](/filings/0000950170-25-104565.md) | [34.9](/filings/0001193125-25-268096.md) | [35.3](/filings/0001193125-26-210355.md) | [35.4](/filings/0001193125-26-333862.md) | [37.9](/filings/0001193125-25-268096.md) | [47.2](/filings/0001193125-26-210355.md) | [47.5](/filings/0001193125-26-333862.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 47,978,286 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-333862.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.